Account
Articles
08.09.2025
Innovative Payment Models: Outcomes‑Based, Annui...

In 2010, the world’s most expensive therapy was Soliris (eculizumab), costing around USD 409,500 p...

Read more
Articles
08.09.2025
ATMP pricing landscape: why traditional models bre...

A €3 million invoice for a single infusion can dazzle as easily as it alarms. Gene therapies such ...

Read more
News
01.06.2022
PMA Insights: Week 22

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Insider Insights
01.02.2022
Committee recommends rejecting Rx to non-Rx reques

The committee’s recommendations are forwarded to the Federal Ministry of Health for consideration.

Read more
Articles
16.12.2020
New PMPRB guidelines in Canada

The Patented Medicine Prices Review Board (PMPRB) has a mandate to ensure that patented medicines ar...

Read more
Articles
05.06.2017
New parallel consultation process

A one stop shop for joint advice between EMA, EUnetHTA and health technology assessment bodies - the...

Read more
News
19.02.2015
Should the UK have a cost per QALY threshold

Should the UK have a cost per QALY threshold

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.